Drug Trial Radar · NCT00412867
Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke (Japan Alteplase Clinical Trial Ⅱ:J-ACT Ⅱ)
Last checked: Nov 20, 2026Latest source record: Jan 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
58
Actual
Start
Dec 2006
Primary completion
Jun 2008
Study completion Jun 2008
Sponsor
- Lead sponsor
- Tanabe Pharma CorporationIndustry
- Sponsor type
- Industry
- Collaborators
- Kyowa Kirin Co., Ltd.
- First posted
- Dec 19, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to confirm the efficacy and safety of intravenously administered alteplase in patients with acute ischemic stroke based on the rate of recanalization assessed by magnetic resonance angiography (MRA), the rate of patients with a modified Rankin Scale (mRS) score of 0-1, and the incidence of symptomatic intracranial hemorrhage (sICH), in comparison with the data reported in the current literature.
Conditions
- Stroke
Interventions
AlteplaseDrug
0.6 mg/kg of Alteplase is intravenously administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With Valid Recanalization Assessed by Magnetic Resonance Angiography (MRA)Time frame: within 6 hours, from 24 to 36 hours after onset
- Number of Patients With a Modified Rankin Scale (mRS) Score of 0-1 a 3 MonthsTime frame: 3 months after onset
- Number of Patients With Symptomatic Intracranial Hemorrhage (sICH) Within 36 HoursTime frame: within 36 hours after starting treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigational site 01
Hokkaido, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.